| 1. |
Siegel RL, Kratzer TB, Giaquinto AN, et al. Cancer statistics, 2025. CA Cancer J Clin, 2025, 75(1): 10-45.
|
| 2. |
Diao X, Guo C, Jin Y, et al. Cancer situation in China: an analysis based on the global epidemiological data released in 2024. Cancer Commun (Lond), 2025, 45(2): 178-197.
|
| 3. |
中華醫學會腫瘤學分會. 中華醫學會肺癌臨床診療指南 (2025版). 中華腫瘤雜志, 2025, 47(9): 769-810.Chinese Society of Oncology, Chinese Medical Association. Chinese Medical Association guidelines for clinical diagnosis and treatment of lung cancer (2025 edition). Chin J Oncol, 2025, 47(9): 769-810.
|
| 4. |
Wood DE, Kazerooni EA, Aberle DR, et al. NCCN Guidelines? insights: lung cancer screening, Version 1. 2025. J Natl Compr Canc Netw, 2025, 23(1): e250002.
|
| 5. |
Fernández-Sáenz FK, de la Torre-Perez L, Baldwin DR, et al. Screening for lung cancer: a systematic review of overdiagnosis and its implications. Mol Oncol, 2024, 18(1): 6-41.
|
| 6. |
Edelman Saul E, Guerra RB, Edelman Saul M, et al. The challenges of implementing low-dose computed tomography for lung cancer screening in low- and middle-income countries. Nat Cancer, 2020, 1(12): 1140-1152.
|
| 7. |
Jiaming Y, Haishen Z, Shi X, et al. Clinical difference between solitary and multiple pulmonary adenocarcinoma nodules. Tumori, 2025, 111(2): 139-146.
|
| 8. |
Wu Q, Zhao S, Huang Y, et al. Correlation between lung cancer probability and number of pulmonary nodules in baseline computed tomography lung cancer screening: a retrospective study based on the Chinese population. Front Oncol, 2023, 12: 1061242.
|
| 9. |
Yu R, Liu D, Yang Y, et al. Expression profiling-based clustering of healthy subjects recapitulates classifications defined by clinical observation in Chinese medicine. J Genet Genomics, 2017, 44(4): 191-197.
|
| 10. |
Li L, Li T, Liang X, et al. A decrease in Flavonifractor plautii and its product, phytosphingosine, predisposes individuals with phlegm-dampness constitution to metabolic disorders. Cell Discov, 2025, 11(1): 25.
|
| 11. |
Chen Y, Wu Y, Yao H, et al. miRNA expression profile of saliva in subjects of Yang deficiency constitution and Yin deficiency constitution. Cell Physiol Biochem, 2018, 49(5): 2088-2098.
|
| 12. |
Yao H, Mo S, Wang J, et al. Genome-wide DNA methylation profiles of phlegm-dampness constitution. Cell Physiol Biochem, 2018, 45(5): 1999-2008.
|
| 13. |
趙圓圓. 肺結節患者臨床特征及中醫體質分布規律探析. 成都中醫藥大學, 2022.Zhao YY. Analysis of the clinical characteristics of patients with pulmonary nodules and the distribution law of TCM constitution. Chengdu University of Traditional Chinese Medicine, 2022.
|
| 14. |
謝柏勝. 孤立性肺結節風險因素分析和患者中醫體質相關性研究. 浙江中醫藥大學, 2016.Xie BS. Risk factor analysis of the patients with solitary pulmonary nodules and patients traditional Chinese medicine constitution related analysis. Zhejiang Chinese Medical University, 2016.
|
| 15. |
徐佳儀. 肺部小結節患者中醫體質分布規律探析. 浙江中醫藥大學, 2019.Xu JY. Analysis of the distribution law of TCM constitution in patients with pulmonary nodules. Zhejiang Chinese Medical University, 2019.
|
| 16. |
Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov, 2022, 12(1): 31-46.
|
| 17. |
馬瓊, 曾瀟, 李雪珂, 等. 口腔微生物組與肺癌發生、發展的研究現狀與展望. 科學通報, 2024, 69(3): 381-393.Ma Q, Zeng X, Li XK, et al. Current status and prospects of the relationship between oral microbiome and the occurrence and development of lung cancer. Sci Bull (Beijing), 2024, 69(3): 381-393.
|
| 18. |
Ren YF, Ma Q, Zeng X, et al. Saliva-microbiome-derived signatures: expected to become a potential biomarker for pulmonary nodules (MCEPN-1). BMC Microbiol, 2024, 24(1): 132.
|
| 19. |
任益鋒, 馬瓊, 李芳, 等. 肺結節患者唾液微生物菌群特征分析: 一項前瞻性、非隨機、同期對照試驗. 四川大學學報(醫學版), 2023, 54(6): 1208-1218.Ren YF, Ma Q, Li F, et al. Analysis of salivary microbiota characteristics in patients with pulmonary nodules: a prospective nonrandomized concurrent controlled trial. J Sichuan Univ Med (Sci Ed), 2023, 54(6): 1208-1218.
|
| 20. |
任益鋒, 譚施言, 馬瓊, 等. 基于口腔微生物組學的肺結節 "病證結合" 預測模型構建與評價. 中國胸心血管外科臨床雜志, 2025, 32(8): 1105-1114.Ren YF, Tan SY, Ma Q, et al. Construction and evaluation of a "disease-syndrome combination" prediction model for pulmonary nodules based on oral microbiomics. Chin J Clin Thorac Cardiovasc Surg, 2025, 32(8): 1105-1114.
|
| 21. |
Vogtmann E, Hua X, Yu G, et al. The oral microbiome and lung cancer risk: an analysis of 3 prospective cohort studies. J Natl Cancer Inst, 2022, 114(11): 1501-1510.
|
| 22. |
中華醫學會呼吸病學分會, 中國肺癌防治聯盟專家組. 肺結節診治中國專家共識(2024年版). 中華結核和呼吸雜志, 2024, 47(8): 716-729.Chinese Thoracic Society, Expert Panel of China Lung Cancer Prevention and Treatment Alliance. Chinese expert consensus on the diagnosis and management of pulmonary nodules (2024 edition). Chin J Tuberc Respir Dis, 2024, 47(8): 716-729.
|
| 23. |
中華中醫藥學會. 中醫體質分類與判定(ZYYXH/T157-2009). 世界中西醫結合雜志, 2009, 4(4): 303-304.Chinese Association of Chinese Medicine. Classification and determination of TCM constitution (ZYYXH/T157-2009). World J Integr Tradit West Med, 2009, 4(4): 303-304.
|
| 24. |
夏逸飛, 孫子凱, 丁振洋, 等. 從偏頗體質論孤立性肺結節的中醫辨治. 廣州中醫藥大學學報, 2019, 36(8): 1267-1271.Xia YF, Sun ZK, Ding ZY, et al. Treatment of solitary pulmonary nodules with Chinese medicine based on biased constitution. J Guangzhou Univ Tradit Chin Med, 2019, 36(8): 1267-1271.
|
| 25. |
Freiman MR, Clark JA, Slatore CG, et al. Patients' knowledge, beliefs, and distress associated with detection and evaluation of incidental pulmonary nodules for cancer: results from a multicenter survey. J Thorac Oncol, 2016, 11(5): 700-708.
|
| 26. |
Li L, Zhao Y, Li H. Assessment of anxiety and depression in patients with incidental pulmonary nodules and analysis of its related impact factors. Thorac Cancer, 2020, 11(6): 1433-1442.
|
| 27. |
王麗娜, 韋媛媛, 胡華青, 等. 肺結節患者焦慮抑郁與Th17/Treg和炎癥水平改變的相關性研究. 中國肺癌雜志, 2020, 23(7): 554-560.Wang LN, Wei YY, Hu HQ, et al. Correlation between anxiety, depression and changes in Th17/Treg and inflammatory levels in patients with pulmonary nodules. Chin J Lung Cancer, 2020, 23(7): 554-560.
|
| 28. |
李麗杰, 宮曉燕, 王爽. 宮曉燕辨治孤立性肺結節病機思路. 吉林中醫藥, 2021, 41(3): 359-362.Li LJ, Gong XY, Wang S. Gong Xiaoyan's ideas on differentiating the pathogenesis of solitary pulmonary nodule. Jilin J Tradit Chin Med, 2021, 41(3): 359-362.
|
| 29. |
朱澤鍇. 基于真實世界研究加味散結湯加減治療中危型孤立性肺結節的臨床療效觀察. 黑龍江中醫藥大學, 2025.Zhu ZK. Clinical efficacy of modified Sanjie decoction for intermediate-risk solitary pulmonary nodules: a real-world study. Heilongjiang University of Chinese Medicine, 2025.
|
| 30. |
夏宇. 加味柴胡疏肝散治療肝郁氣滯證肺結節的臨床療效觀察. 南京中醫藥大學, 2024.Xia Y. Clinical observation on the efficacy of modified Chaihu Shugan San in treating pulmonary nodules with liver qi stagnation syndrome. Nanjing University of Chinese Medicine, 2024.
|
| 31. |
徐皓瑞, 朱博冉, 徐慧楠, 等. 從絡辨治肺癌理法鉤玄. 中醫腫瘤學雜志, 2025, 7(5): 65-73.Xu HR, Zhu BR, Xu HN, et al. Elucidation of the principles and methods for treating lung cancer from the perspective of collateral disease theory. J Tradit Chin Oncol, 2025, 7(5): 65-73.
|
| 32. |
雷勇, 楊永, 程培育, 等. 基于 "陽虛陰盛" 從三焦論治肺結節. 中國中醫基礎醫學雜志, 2025, 31(8): 1446-1449.Lei Y, Yang Y, Cheng PY, et al. Treatment of pulmonary nodules from the perspective of Triple Energizer based on "Yang deficiency and Yin excess". Chin J Basic Med Tradit Chin Med, 2025, 31(8): 1446-1449.
|
| 33. |
李晨雨. 低中危多發性肺結節的中醫體質、中醫證候分布規律及其相關性分析. 廣州中醫藥大學, 2024.Li CY. Analysis of TCM syndrome types, TCM constitution and correlation in patients with multiple pulmonary nodules. Guangzhou University of Chinese Medicine, 2024.
|
| 34. |
吉琳, 申琪, 郭向東. 陽虛動物模型及檢測指標的研究進展. 中國比較醫學雜志, 2021, 31(1): 138-145.Ji L, Shen Q, Guo XD. Research progress in developing an animal model and detection index for Yang deficiency. Chin J Comp Med, 2021, 31(1): 138-145.
|
| 35. |
陳美池. 肺結節的中醫證素分布規律及與免疫細胞水平的相關性研究. 北京中醫藥大學, 2023.Chen MC. Distribution patterns of TCM syndrome elements in pulmonary nodules and their correlation with immune cell levels. Beijing University of Chinese Medicine, 2023.
|
| 36. |
Lin X, Yu Z, Liu Y, et al. Gut-X axis. iMeta, 2025, 4(1): e270.
|
| 37. |
Luo J, Zhao T, Su W, et al. Relationship of Mogibacterium in the gut microbiota with early-stage lung cancer. J Appl Microbiol, 2025, 136(6): lxaf130.
|
| 38. |
鄭娟. 單發性與多發性肺結節的臨床特征分析. 大連醫科大學, 2021.Zheng J. Clinical characteristics analyses of solitary and multiple pulmonary nodules. Dalian Medical University, 2021.
|
| 39. |
Schaus SR, Vasconcelos Pereira G, Luis AS, et al. Ruminococcus torques is a keystone degrader of intestinal mucin glycoprotein, releasing oligosaccharides used by Bacteroides thetaiotaomicron. mBio, 2024, 15(8): e0003924.
|
| 40. |
Valentino V, De Filippis F, Marotta R, et al. Genomic features and prevalence of Ruminococcus species in humans are associated with age, lifestyle, and disease. Cell Rep, 2024, 43(12): 115018.
|
| 41. |
Zheng Y, Fang Z, Xue Y, et al. Specific gut microbiome signature predicts the early-stage lung cancer. Gut Microbes, 2020, 11(4): 1030-1042.
|
| 42. |
Newsome RC, Gharaibeh RZ, Pierce CM, et al. Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort. Genome Med, 2022, 14(1): 35.
|
| 43. |
Wang Z, Maschera B, Lea S, et al. Airway host-microbiome interactions in chronic obstructive pulmonary disease. Respir Res, 2019, 20(1): 113.
|
| 44. |
Mannion JM, McLoughlin RM, Lalor SJ. The airway microbiome-IL-17 axis: a critical regulator of chronic inflammatory disease. Clin Rev Allergy Immunol, 2023, 64(2): 161-178.
|
| 45. |
Shen W, Tang D, Deng Y, et al. Association of gut microbiomes with lung and esophageal cancer: a pilot study. World J Microbiol Biotechnol, 2021, 37(8): 128.
|
| 46. |
Wang X, Fang Y, Liang W, et al. Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer. Cancer Cell, 2024, 42(10): 1729-1746. e8.
|
| 47. |
茆曉妍, 萬宗仁, 楊丹, 等. 宏基因組二代測序下慢性阻塞性肺疾病急性加重期患者痰菌群研究. 中國呼吸與危重監護雜志, 2023, 22(3): 168-175.Mao XY, Wan ZR, Yang D, et al. Analysis of sputum flora in patients with acute exacerbation of chronic obstructive pulmonary disease basing on metagenomic next generation sequencing. Chin J Respir Crit Care Med, 2023, 22(3): 168-175.
|
| 48. |
Hazra D, Sm F, Chawla K, et al. The altered sputum microbiome profile in patients with moderate and severe COPD exacerbations, compared to the healthy group in the Indian population. F1000Res, 2023, 12: 528.
|
| 49. |
Oh S, An S, Park K, et al. Gut microbial signatures in long COVID: potential biomarkers and therapeutic targets. Infect Dis Ther, 2025, 14(7): 1461-1475.
|
| 50. |
Zhao Z, Fei K, Bai H, et al. Metagenome association study of the gut microbiome revealed biomarkers linked to chemotherapy outcomes in locally advanced and advanced lung cancer. Thorac Cancer, 2021, 12(1): 66-78.
|
| 51. |
Chua HH, Chou HC, Tung YL, et al. Intestinal dysbiosis featuring abundance of Ruminococcus gnavus associates with allergic diseases in infants. Gastroenterology, 2018, 154(1): 154-167.
|
| 52. |
Luki? I, Getselter D, Ziv O, et al. Antidepressants affect gut microbiota and Ruminococcus flavefaciens is able to abolish their effects on depressive-like behavior. Transl Psychiatry, 2019, 9(1): 133.
|
| 53. |
Zhang WQ, Zhao SK, Luo JW, et al. Alterations of fecal bacterial communities in patients with lung cancer. Am J Transl Res, 2018, 10(10): 3171-3185.
|
| 54. |
Liu P, Liu Z, Wang J, et al. Immunoregulatory role of the gut microbiota in inflammatory depression. Nat Commun, 2024, 15(1): 3003.
|
| 55. |
梁秋然, 秦亞斌, 張阿潤, 等. 腸道菌群與肺結節惡性程度相關性高通量測序關聯研究. 腫瘤學雜志, 2024, 30(12): 1006-1013.Liang QR, Qin YB, Zhang AR, et al. Association of gut microbiota with the malignant degree of pulmonary nodules. J Chin Oncol, 2024, 30(12): 1006-1013.
|
| 56. |
Martín R, Rios-Covian D, Huillet E, et al. Faecalibacterium: a bacterial genus with promising human health applications. FEMS Microbiol Rev, 2023, 47(4): fuad039.
|
| 57. |
Vernocchi P, Gili T, Conte F, et al. Network analysis of gut microbiome and metabolome to discover microbiota-linked biomarkers in patients affected by non-small cell lung cancer. Int J Mol Sci, 2020, 21(22): 8730.
|
| 58. |
Haberman Y, Kamer I, Amir A, et al. Gut microbial signature in lung cancer patients highlights specific taxa as predictors for durable clinical benefit. Sci Rep, 2023, 13(1): 2007.
|
| 59. |
Yang Y, Ye M, Song Y, et al. Gut microbiota and SCFAs improve the treatment efficacy of chemotherapy and immunotherapy in NSCLC. NPJ Biofilms Microbiomes, 2025, 11(1): 146.
|
| 60. |
Wang Q, Yao S. Molecular basis for cold-intolerant Yang-deficient constitution of traditional Chinese medicine. Am J Chin Med, 2008, 36(5): 827-834.
|
| 61. |
張阿潤. 肺結節陽虛證型患者腸道菌群特征觀察研究. 北京中醫藥大學, 2023.Zhang AR. Observation on characteristics of intestinal flora in patients with pulmonary nodules of Yang deficiency pattern. Beijing University of Chinese Medicine, 2023.
|